Clinical development failure
Programs are still in early-stage testing and may not demonstrate sufficient safety or efficacy.
- Scope
- OpRegen, OPC1, ReSonance
- Materiality
- high
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic, or off-the-shelf, cell therapies for serious ophthalmic and neurological diseases. It uses a proprietary pluripotent-cell platform, AlloSCOPE, to design, manufacture, and test specialized human cells intended to replace or support damaged tissue, often through collaborations with larger pharmaceutical partners.
−246,8 %
−436,5 %
+53,2 %
5.20
5.20
| % | |
|---|---|
| Clinical-stage cell therapies | 20% Lead therapeutic candidates in human trials for ophthalmic and neurological diseases. |
| Preclinical cell therapies | 10% Earlier-stage programs being advanced through internal development or partnerships. |
| Collaborative development revenue | 60% Revenue from research, development, and license collaborations with partners such as Roche. |
| Platform and manufacturing capabilities | 10% Cell engineering, banking, formulation, and cGMP production capabilities used across programs. |
Lineage Cell Therapeutics sells primarily to pharmaceutical and biotech collaborators rather than end patients, with...
- Pharmaceutical collaboration partnersprimary
Buy development rights, access to assets, and platform expertise to advance cell therapy programs.
- Strategic biotech partnerssecondary
Partner on preclinical or early clinical assets where shared development reduces risk and cost.
- Government and grant agenciessecondary
Provide non-dilutive funding for research and development of selected programs.
- Patients in target indicationsemerging
The eventual end users of the therapies, especially in ophthalmology and neurology.
The company is headquartered in the United States, but its development footprint is international through...
- •United States headquarters and primary corporate base
- •Israel facilities support part of the operating footprint
- •Worldwide Roche collaboration expands OpRegen development reach
- •International partner structure increases regulatory and execution complexity
- •No country-level revenue disclosure was provided in the excerpts
Lineage’s strategy is to use its AlloSCOPE platform to create a pipeline of related allogeneic cell therapy assets that...
01
Advance OpRegen in partnership with Rocheshort-term
The lead ophthalmology program is the most advanced asset and a key source of validation.
02
Scale and de-risk manufacturingmedium-term
Reliable, reproducible cell production is essential for clinical supply and eventual commercialization.
03
Expand the partnered pipelinemedium-term
Additional collaborations can fund development and increase the value of the platform.
The company faces the classic risks of clinical-stage biotech: uncertain trial outcomes, regulatory delay, and...
Manufacturing and cell-bank contamination
Allogeneic cell therapies depend on stable cell lines and reproducible cGMP production.
- Scope
- Foundational cell lines and cell banks
- Materiality
- high
Regulatory uncertainty for novel cell therapies
There is limited precedent for pluripotent stem cell-derived and iPSC-derived approvals.
- Scope
- FDA and other major markets
- Materiality
- high
Third-party device and supply dependence
Specialized delivery systems may be needed and could be unavailable or fail performance standards.
- Scope
- Administration tools and devices
- Materiality
- medium
Geopolitical disruption in Israel
Facilities and employees in Israel may be affected by regional conflict and mobilization.
- Scope
- Israel operations
- Materiality
- medium
Revenue recognition under collaborative agreements
Affects reported revenue timing and comparability
Intangible asset impairment
Can materially affect earnings and balance sheet value
Warrant liability or equity classification
Can create non-cash gains or losses
Deferred taxes and tax reserves
Affects tax expense and net loss
: 28.4.2026